Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for chronic kidney disease progression in type 2 diabetes
NL-OMON54810Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) comparing Semaglutide + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary composite renal and cardiovascular endpoint. Started Jul 2019; status: active, not recruiting.
02
Drugs
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON54810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54810.